ClinicalTrials.gg
CompletedNCT05431634Updated May 9, 2023

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

A Phase 1 interventional study of Experimental drug: ESK-001 and Placebo in Safety and Tolerability, sponsored by Alumis Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by Alumis Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)

02

Conditions studied

  • Safety and Tolerability
03

In context

Lead sponsor

Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit
  • Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters
  • Other inclusions as specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Participant has a prior exposure to ESK-001
  • Participant has a history of to any of the ingredients of ESK-001
  • Other exclusions as specified in the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for ESK-001

    Other: Placebo

  • Experimental
    Experimental Drug ESK-001

    Experimental Drug ESK-001

    Drug: Experimental drug: ESK-001

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs)

    Safety and tolerability

    Time frame: Up to 14 days

  2. Incidence of Serious Adverse Events (SAEs)

    Safety and tolerability

    Time frame: Up to 14 days

Secondary outcomes

  1. The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14

    Pharmacokinetics

    Time frame: Up to 14 days

  2. The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14

    Pharmacokinetics

    Time frame: Up to 14 days

  3. The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.

    Pharmacokinetics

    Time frame: Up to 14 days

  4. The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.

    Pharmacokinetics

    Time frame: Up to 14 days

  5. Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14

    Pharmacokinetics

    Time frame: Up to 14 days

  6. Apparent clearance CL(Clearance)/F for ESK001 on Day 1

    Pharmacokinetics

    Time frame: Up to 14 days

  7. The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14

    Pharmacokinetics

    Time frame: Up to 14 days

  8. The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.

    Pharmacokinetics

    Time frame: Up to 14 days

  9. Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001

    Pharmacodynamics

    Time frame: 14 days after first dose

07

Study locations

1 site
  • Alumis Central site
    Glendale, California 91206, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Dec 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 24, 2022
StartActual
May 12, 2022
Primary completionActual
Dec 1, 2022
CompletionActual
Dec 31, 2022
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05431634
Lead sponsor
Alumis Inc
Responsible party
Sponsor
First posted
Jun 24, 2022
Start date
May 12, 2022
Primary completion
Dec 1, 2022
Completion
Dec 31, 2022
Last update
May 9, 2023

Study contacts

Mark Bradley
study director · Alumis Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Envudeucitinib

Start the discussion